{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-24-000127","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.819065+00:00","generated_at":"2026-05-30T01:04:06.061477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M","bullets":["Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.","Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.","Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.","Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.","Cash and marketable securities of $317.0M as of September 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-24-000127","json":"https://secwatch.observer/filing/0001819790-24-000127.json","markdown":"https://secwatch.observer/filing/0001819790-24-000127.md","text":"https://secwatch.observer/filing/0001819790-24-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/0001819790-24-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/tars-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:04:06.061477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}